Peregrine Ophthalmic

Executive Summary

Peregrine Ophthalmic Pte Ltd, founded in 2013 in Singapore, is a nanomedicine company developing innovative ophthalmic therapies using its proprietary liposomal drug delivery platform. The company's lead product, Lipolat, is a sustained-release formulation of latanoprost designed to improve the treatment of glaucoma by reducing intraocular pressure with less frequent dosing. Additionally, Lipolat is being explored for steatoblepharon, a condition involving fat deposits in the eyelids, representing a novel cosmetic ophthalmology application. Having completed Phase 1 trials with favorable safety and efficacy data, Peregrine is now advancing Lipolat into Phase 2 clinical studies. The company occupies a unique position at the intersection of glaucoma therapeutics and cosmetic ophthalmology, with liposomal technology potentially offering differentiation from existing prostaglandin analogs. With a lean team of 10-50 employees and no disclosed funding rounds, Peregrine may seek partnership or additional financing to support its clinical programs. Near-term catalysts include Phase 2 initiation, interim data readouts, and potential strategic collaborations to advance the pipeline toward commercialization.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Clinical Trial Initiation for Lipolat in Glaucoma80% success
• Q2 2027Interim Efficacy Data from Phase 2 Study60% success
• Q4 2026Partnership or Licensing Agreement for Lipolat40% success